BRIEF-Oragenics Updates Shareholders On Concussion Drug Progress

Reuters10-09

Oct 9 (Reuters) - Oragenics Inc :

* ORAGENICS, INC. UPDATES SHAREHOLDERS ON CONCUSSION DRUG PROGRESS AND PHASE II TRIAL PREPARATION

* ORAGENICS INC - PREPARING TO INITIATE PHASE II CLINICAL TRIALS FOR ONP-002

* ORAGENICS: IN PREPARATION FOR UPCOMING PHASE II CLINICAL TRIALS PLANS TO SUBMIT AUSTRALIAN REGULATORY SUBMISSION BROCHURE DURING Q4

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474249707?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-09 19:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2474249707","market":"us","top_or_hot":-1,"title":"BRIEF-Oragenics Updates Shareholders On Concussion Drug Progress","media":"Reuters","content":"<html><body><p>Oct 9 (Reuters) - Oragenics Inc   :</p><p>   * ORAGENICS, INC. UPDATES SHAREHOLDERS ON CONCUSSION DRUG PROGRESS AND PHASE II TRIAL PREPARATION</p><p>   * ORAGENICS INC - PREPARING TO INITIATE PHASE II CLINICAL TRIALS FOR ONP-002</p><p>   * ORAGENICS:  IN PREPARATION FOR UPCOMING PHASE II CLINICAL TRIALS PLANS TO SUBMIT AUSTRALIAN REGULATORY SUBMISSION BROCHURE DURING Q4</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Oragenics Updates Shareholders On Concussion Drug Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Oragenics Updates Shareholders On Concussion Drug Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-09 19:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 9 (Reuters) - Oragenics Inc   :   * ORAGENICS, INC. UPDATES SHAREHOLDERS ON CONCUSSION DRUG PROGRESS AND PHASE II TRIAL PREPARATION   * ORAGENICS INC - PREPARING TO INITIATE PHASE II CLINICAL ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OGEN","symbol_name":"Oragenics Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2474249707","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474249707","pubTimestamp":1728475068,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 9  - Oragenics Inc   :   * ORAGENICS, INC. UPDATES SHAREHOLDERS ON CONCUSSION DRUG PROGRESS AND PHASE II TRIAL PREPARATION   * ORAGENICS INC - PREPARING TO INITIATE PHASE II CLINICAL TRIALS FOR ONP-002   * ORAGENICS:  IN PREPARATION FOR UPCOMING PHASE II CLINICAL TRIALS PLANS TO SUBMIT AUSTRALIAN REGULATORY SUBMISSION BROCHURE DURING Q4Source text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OGEN":"Oragenics Inc.","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","PRGS":"Progress Software Corporation","BK4097":"系统软件","BK4139":"生物科技"},"translate_title":"简报-Oragenics向股东通报脑震荡药物进展的最新情况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OGEN":1,"PRGS":1},"content_text":"Oct 9 (Reuters) - Oragenics Inc   :   * ORAGENICS, INC. UPDATES SHAREHOLDERS ON CONCUSSION DRUG PROGRESS AND PHASE II TRIAL PREPARATION   * ORAGENICS INC - PREPARING TO INITIATE PHASE II CLINICAL TRIALS FOR ONP-002   * ORAGENICS:  IN PREPARATION FOR UPCOMING PHASE II CLINICAL TRIALS PLANS TO SUBMIT AUSTRALIAN REGULATORY SUBMISSION BROCHURE DURING Q4Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474249707"}